Unknown

Dataset Information

0

Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia.


ABSTRACT: To determine the maximum-tolerated dose (MTD) of the histone deacetylase inhibitor vorinostat combined with fixed doses of cytarabine (ara-C or cytosine arabinoside) and etoposide in patients with poor-risk or advanced acute leukemia, to obtain preliminary efficacy data, describe pharmacokinetics, and in vivo pharmacodynamic effects of vorinostat in leukemia blasts.In this open-label phase I study, vorinostat was given orally on days one to seven at three escalating dose levels: 200 mg twice a day, 200 mg three times a day, and 300 mg twice a day. On days 11 to 14, etoposide (100 mg/m(2)) and cytarabine (1 or 2 g/m(2) twice a day if ?65 or <65 years old, respectively) were given. The study used a standard 3+3 dose escalation design.Eighteen of 21 patients with acute myelogenous leukemia (AML) treated on study completed planned therapy. Dose-limiting toxicities [hyperbilirubinemia/septic death (1) and anorexia/fatigue (1)] were encountered at the 200 mg three times a day level; thus, the MTD was established to be vorinostat 200 mg twice a day. Of 21 patients enrolled, seven attained a complete remission (CR) or CR with incomplete platelet recovery, including six of 13 patients treated at the MTD. The median remission duration was seven months. No differences in percentage S-phase cells or multidrug resistance transporter (MDR1 or BCRP) expression or function were observed in vivo in leukemia blasts upon vorinostat treatment.Vorinostat 200 mg twice a day can be given safely for seven days before treatment with cytarabine and etoposide. The relatively high CR rate seen at the MTD in this poor-risk group of patients with AML warrants further studies to confirm these findings.

SUBMITTER: Gojo I 

PROVIDER: S-EPMC4332848 | biostudies-literature | 2013 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia.

Gojo Ivana I   Tan Ming M   Fang Hong-Bin HB   Sadowska Mariola M   Lapidus Rena R   Baer Maria R MR   Carrier France F   Beumer Jan H JH   Anyang Bean N BN   Srivastava Rakesh K RK   Espinoza-Delgado Igor I   Ross Douglas D DD  

Clinical cancer research : an official journal of the American Association for Cancer Research 20130212 7


<h4>Purpose</h4>To determine the maximum-tolerated dose (MTD) of the histone deacetylase inhibitor vorinostat combined with fixed doses of cytarabine (ara-C or cytosine arabinoside) and etoposide in patients with poor-risk or advanced acute leukemia, to obtain preliminary efficacy data, describe pharmacokinetics, and in vivo pharmacodynamic effects of vorinostat in leukemia blasts.<h4>Experimental design</h4>In this open-label phase I study, vorinostat was given orally on days one to seven at th  ...[more]

Similar Datasets

| S-EPMC4247259 | biostudies-literature
| S-EPMC9150866 | biostudies-literature
| S-EPMC3079070 | biostudies-literature
2017-05-22 | GSE69958 | GEO
2017-05-22 | GSE69957 | GEO
| S-EPMC3091219 | biostudies-literature
2015-02-18 | GSE37529 | GEO
2017-05-22 | GSE69956 | GEO
| S-EPMC5709258 | biostudies-literature
| S-EPMC10111346 | biostudies-literature